Kyorin unveils new oral dose plant

Japan's Kyorin Pharmaceuticals plans to invest some 8 billion yen
(€62.5m) in a new facility to produce tablet and capsule
formulations.

Japan's Kyorin Pharmaceuticals plans to invest some 8 billion yen (€62.5m) in a new facility to produce tablet and capsule formulations. This will replace an existing plant in Nogi, Tochigi prefecture and is scheduled for completion in April 2006.

The existing Nogi unit, which makes eye drops and other products including internal medicines, will be closed in March 2006 and Kyorin will outsource production of intravenous agents and medicines made in small quantities to other companies, reports the Nihon Keizai Shimbun.

Kyorin was hit recently by the Japanese Ministry of Health, Labour and Welfare's decision to an emergency safety notice regarding the safety of Gatiflo (gatifloxacin), the company's top-selling antibacterial product.

Related news

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Follow us

Products

View more

Webinars